Jazz Pharmaceuticals Public (Nasdaq: JAZZ ) reported earnings on Feb. 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Jazz Pharmaceuticals Public missed slightly on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP earnings per share increased significantly.
Gross margins dropped, operating margins dropped, net margins increased.
Jazz Pharmaceuticals Public logged revenue of $181.9 million. The 11 analysts polled by S&P Capital IQ expected revenue of $185.3 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $83.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $3.27. The 13 earnings estimates compiled by S&P Capital IQ predicted $1.41 per share. GAAP EPS of $3.27 for Q4 were 314% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 86.0%, 940 basis points worse than the prior-year quarter. Operating margin was 36.7%, much worse than the prior-year quarter. Net margin was 109.2%, much better than the prior-year quarter.
Next quarter's average estimate for revenue is $185.8 million. On the bottom line, the average EPS estimate is $1.26.
Next year's average estimate for revenue is $809.8 million. The average EPS estimate is $5.69.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 213 members out of 278 rating the stock outperform, and 65 members rating it underperform. Among 75 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 58 give Jazz Pharmaceuticals Public a green thumbs-up, and 17 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals Public is buy, with an average price target of $66.91.